Beta Bionics taps Senseonics’ implantable glucose monitor for artificial pancreas

This article was originally published here

Senseonics‘ (NYSE:SENS) said today that it inked a deal to integrate glucose data from its Eversense continuous glucose monitoring system into Beta Bionics‘ investigational iLet bionic pancreas.

According to the terms of the development agreement, Beta Bionics and Senseonics will work together to combine the two systems in the hopes of driving insulin and glucagon dosing with real-time data from the Eversense monitor.

Get the full story at our sister site, Drug Delivery Business News.

The post Beta Bionics taps Senseonics’ implantable glucose monitor for artificial pancreas appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply